| Exceptional Behavioral Health Services Llc | |
|
2439 Manhattan Blvd Ste 308 Harvey LA 70058-5328 | |
| (504) 235-7778 | |
| (504) 366-5260 |
| Full Name | Exceptional Behavioral Health Services Llc |
|---|---|
| Speciality | Clinic/Center |
| Location | 2439 Manhattan Blvd, Harvey, Louisiana |
| Authorized Official Name and Position | Tanika Andrews (CEO/OWNER) |
| Authorized Official Contact | 5042357778 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Exceptional Behavioral Health Services Llc 2439 Manhattan Blvd Ste 308 Harvey LA 70058-5328 Ph: (504) 235-7778 | Exceptional Behavioral Health Services Llc 2439 Manhattan Blvd Ste 308 Harvey LA 70058-5328 Ph: (504) 235-7778 |
| NPI Number | 1235473133 |
|---|---|
| Provider Enumeration Date | 11/15/2012 |
| Last Update Date | 06/23/2023 |
| Certification Date | 06/23/2023 |
| Medicare PECOS PAC ID | 4183985062 |
|---|---|
| Medicare Enrollment ID | O20180312000913 |
News Archive
A new strategic plan from an arm of the National Institutes of Health envisions scientists being able to identify genetic bases of most single-gene disorders and gaining new insights into multi-gene disorders in the next decade. This should lead to more accurate diagnoses, new drug targets and the development of practical treatments for many who today lack therapeutic options, according to the plan from the National Human Genome Research Institute (NHGRI).
Gilead Sciences, Inc. and Galapagos NV today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents.
The Garvan Institute of Medical Research announces the launch of spin-off company Solvanix Pty Ltd, set up to commercialise a novel technology that will improve the stability of therapeutic monoclonal antibodies.
Autism. What is its cause? How does it affect brain anatomy, electrophysiology, visual function and perception? What must we do to meet the needs of these patients? How can optometrists as health care providers be in the vanguard for screening for this spectrum of disorders?
Global regenerative medicine company Mesoblast Limited (ASX:MSB) has announced that its Phase 2 clinical trial investigating the use of allogeneic, or off-the-shelf, Mesenchymal Precursor Cells (MPCs) for non-surgical restoration of degenerated intervertebral discs and treatment of low back pain has enrolled 50% of the total study patients. This rapid rate of enrolment attests to the major unmet medical need and to the relative simplicity of Mesoblast's non-surgical procedure. Mesoblast expects to complete full enrolment by early third quarter.
› Verified 7 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235473133 | NPI | - | NPPES |
| Provider Name | Bennett O Nwankpa |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1043341944 PECOS PAC ID: 2668533720 Enrollment ID: I20081208000280 |
News Archive
A new strategic plan from an arm of the National Institutes of Health envisions scientists being able to identify genetic bases of most single-gene disorders and gaining new insights into multi-gene disorders in the next decade. This should lead to more accurate diagnoses, new drug targets and the development of practical treatments for many who today lack therapeutic options, according to the plan from the National Human Genome Research Institute (NHGRI).
Gilead Sciences, Inc. and Galapagos NV today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents.
The Garvan Institute of Medical Research announces the launch of spin-off company Solvanix Pty Ltd, set up to commercialise a novel technology that will improve the stability of therapeutic monoclonal antibodies.
Autism. What is its cause? How does it affect brain anatomy, electrophysiology, visual function and perception? What must we do to meet the needs of these patients? How can optometrists as health care providers be in the vanguard for screening for this spectrum of disorders?
Global regenerative medicine company Mesoblast Limited (ASX:MSB) has announced that its Phase 2 clinical trial investigating the use of allogeneic, or off-the-shelf, Mesenchymal Precursor Cells (MPCs) for non-surgical restoration of degenerated intervertebral discs and treatment of low back pain has enrolled 50% of the total study patients. This rapid rate of enrolment attests to the major unmet medical need and to the relative simplicity of Mesoblast's non-surgical procedure. Mesoblast expects to complete full enrolment by early third quarter.
› Verified 7 days ago
News Archive
A new strategic plan from an arm of the National Institutes of Health envisions scientists being able to identify genetic bases of most single-gene disorders and gaining new insights into multi-gene disorders in the next decade. This should lead to more accurate diagnoses, new drug targets and the development of practical treatments for many who today lack therapeutic options, according to the plan from the National Human Genome Research Institute (NHGRI).
Gilead Sciences, Inc. and Galapagos NV today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents.
The Garvan Institute of Medical Research announces the launch of spin-off company Solvanix Pty Ltd, set up to commercialise a novel technology that will improve the stability of therapeutic monoclonal antibodies.
Autism. What is its cause? How does it affect brain anatomy, electrophysiology, visual function and perception? What must we do to meet the needs of these patients? How can optometrists as health care providers be in the vanguard for screening for this spectrum of disorders?
Global regenerative medicine company Mesoblast Limited (ASX:MSB) has announced that its Phase 2 clinical trial investigating the use of allogeneic, or off-the-shelf, Mesenchymal Precursor Cells (MPCs) for non-surgical restoration of degenerated intervertebral discs and treatment of low back pain has enrolled 50% of the total study patients. This rapid rate of enrolment attests to the major unmet medical need and to the relative simplicity of Mesoblast's non-surgical procedure. Mesoblast expects to complete full enrolment by early third quarter.
› Verified 7 days ago
Seizing 611 Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 2017 Snowbird Dr, Harvey, LA 70058 Phone: 504-331-7813 | |
Of Sound Mind Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 3420 W Parc Green St, Harvey, LA 70058 Phone: 504-446-4378 | |
Affinity Supportive Healthcare Services Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 2100 Broadway Ave, Harvey, LA 70058 Phone: 504-638-1273 | |
Cornerstone Counseling & Wellness, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1801 Manhattan Blvd Ste J68, Harvey, LA 70058 Phone: 469-713-6354 | |
Above And Beyond Bhps, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 2439 Manhattan Blvd Ste 211, Harvey, LA 70058 Phone: 504-621-3211 Fax: 855-495-2118 | |
Best Behavioral Services Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 2439 Manhattan Blvd # 204, Harvey, LA 70058 Phone: 404-692-0554 | |
Expressive Art Solutions Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 2309 Manhattan Blvd Ste 5, Harvey, LA 70058 Phone: 504-378-6146 |